(Q37848404)

24 August 2017

1 reference

title

Vigabatrin for infantile spasms (English)

1 reference

24 August 2017

Vigabatrin for Infantile Spasms (English)

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

25 November 2024

1 reference

ChEBI release 2020-05-28

Paul Belliveau

1 reference

24 August 2017

Kimberly A. Pesaturo

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21361740

25 November 2024

Linda M. Spooner

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21361740

25 November 2024

language of work or name

English

0 references

publication date

1 March 2011

1 reference

24 August 2017

March 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21361740

full work available at URL

25 November 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1592%2Fphco.31.3.298

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

http://onlinelibrary.wiley.com/wol1/doi/10.1592/phco.31.3.298/fullpdf

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

25 November 2024

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

298-311

1 reference

Medical treatment of patients with infantile spasms.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Effect of food on the absorption of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Cerebrospinal fluid GABA and seizure control with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Clinical pharmacology of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Vigabatrin. Clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Vigabatrin extracellular pharmacokinetics and concurrent gamma-aminobutyric acid neurotransmitter effects in rat frontal cortex and hippocampus using microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Human brain GABA levels rise rapidly after initiation of vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

GABA changes with vigabatrin in the developing human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Prolonged vigabatrin treatment modifies developmental changes of GABA(A)-receptor binding in young children with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

The effect of vigabatrin on brain and platelet GABA-transaminase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Gamma-vinyl GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in epileptic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Vigabatrin for the treatment of infantile spasms: final report of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

A retrospective study on aetiology based outcome of infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

The potential for vigabatrin-induced intramyelinic edema in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Cerebral MRI abnormalities associated with vigabatrin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

A risk-benefit assessment of treatments for infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

21 January 2018

Vigabatrin: 2008 update

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Genetic basis for idiosyncratic reactions to antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

New antiepileptic drugs in pediatric epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Vigabatrin in complex partial seizures: a long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.3.298

Use of the newer antiepileptic drugs in pediatric epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Treatment of pediatric epilepsy: expert opinion, 2005.

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Anticonvulsant action in mice with sound-induced seizures of the optical isomers of gamma-vinyl GABA

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Pharmacokinetics of vigabatrin: implications of creatinine clearance

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Pharmacokinetics of vigabatrin following single and multiple oral doses in normal volunteers

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid)

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Levels of total gamma-aminobutyric acid (GABA), free GABA and homocarnosine in cerebrospinal fluid of epileptic patients before and during gamma-vinyl-GABA (vigabatrin) treatment

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Acute encephalopathy associated with vigabatrin monotherapy in patients with mild renal failure

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate, and glutamine in human brain

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Effects of vigabatrin on the GABAergic system as determined by [123I]iomazenil SPECT and GABA MRS

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

gamma-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Severe persistent visual field constriction associated with vigabatrin

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

Current treatment of West syndrome in Japan

25 November 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.31.3.298

25 November 2024

Identifiers

1 reference

24 August 2017

1 reference